Analysts forecast that Galectin Therapeutics Inc. (NASDAQ:GALT) will report ($0.09) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.07). Galectin Therapeutics posted earnings per share of ($0.07) in the same quarter last year, which indicates a negative year over year growth rate of 28.6%. The firm is expected to report its next quarterly earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.37) per share for the current year, with EPS estimates ranging from ($0.47) to ($0.27). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.51) to ($0.41). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04.

Several research firms have weighed in on GALT. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Thursday, August 15th. ValuEngine downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 18th.

Shares of Galectin Therapeutics stock traded up $0.20 on Friday, hitting $3.79. The company’s stock had a trading volume of 239,689 shares, compared to its average volume of 348,271. The company has a market capitalization of $215.76 million, a P/E ratio of -9.97 and a beta of 3.04. Galectin Therapeutics has a 52-week low of $2.94 and a 52-week high of $6.98. The firm has a fifty day moving average price of $3.44 and a 200-day moving average price of $4.17.

A number of hedge funds have recently bought and sold shares of the stock. Vivaldi Capital Management LLC acquired a new stake in Galectin Therapeutics during the 2nd quarter valued at $44,000. Commonwealth Equity Services LLC raised its holdings in shares of Galectin Therapeutics by 25.1% in the second quarter. Commonwealth Equity Services LLC now owns 15,247 shares of the company’s stock worth $63,000 after acquiring an additional 3,059 shares during the last quarter. Centaurus Financial Inc. raised its holdings in shares of Galectin Therapeutics by 20,098.8% in the second quarter. Centaurus Financial Inc. now owns 16,563 shares of the company’s stock worth $69,000 after acquiring an additional 16,481 shares during the last quarter. Amussen Hunsaker Associates LLC purchased a new stake in shares of Galectin Therapeutics in the second quarter valued at $71,000. Finally, D. E. Shaw & Co. Inc. lifted its position in shares of Galectin Therapeutics by 19.3% in the second quarter. D. E. Shaw & Co. Inc. now owns 19,498 shares of the company’s stock valued at $81,000 after acquiring an additional 3,148 shares in the last quarter. 14.99% of the stock is currently owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Featured Article: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.